- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00009984
Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer
Randomized Phase II Study of Thalidomide Versus Thalidomide Plus Fludarabine for Patients With Chronic Lymphocytic Leukemia Previously Treated With Fludarabine
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
OBJECTIVES:
I. Compare the safety and tolerability of thalidomide with or without fludarabine in patients with fludarabine-refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
II. Compare the incidence of complete and partial remission in patients treated with these regimens.
OUTLINE: This is a randomized, open-label study. Patients are stratified according to time to relapse from last fludarabine treatment (less than 6 months vs more than 6 months). Patients are randomized to one of two treatment arms.
Arm I: Patients receive oral thalidomide once daily in the absence of disease progression or unacceptable toxicity.
Arm II: Patients receive thalidomide as in arm I and fludarabine IV over 30 minutes on days 1-5. Treatment with fludarabine repeats every 28 days for 6 courses. Once fludarabine is completed, patients continue to receive thalidomide alone as in arm I.
PROJECTED ACCRUAL: A total of 24-70 patients (12-35 per treatment arm) will be accrued for this study within 1 year.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
New York
-
Bronx, New York, Förenta staterna, 10467-2490
- Montefiore Medical Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Diagnosis of one of the following:
Confirmed chronic lymphocytic leukemia (CLL), meeting the following criteria:
- Peripheral blood lymphocytosis greater than 5,000/mm^3
- Co-expression of the CD5, CD19, CD20, and CD23 surface antigens
- Clonal kappa and lambda light chain expression
- Dim surface immunoglobulin expression
- Small lymphocytic lymphoma
Relapsed or refractory disease
- Must have received at least 1 prior regimen containing fludarabine
Meets one of the following criteria:
- Recurrence of lymphocytosis greater than 5,000/mm^3 or an increase in lymph node volume greater than 50% after achieving complete (CR) or partial response (PR)
- Never achieved a CR or PR after receiving at least 2 courses of fludarabine IV for 5 days at a dose of 25 mg/m^2/day
- No other lymphoproliferative diseases or diseases due to transformation of CLL (e.g., prolymphocytic leukemia or Richter's syndrome)
- No known CNS disease
- Performance status - Karnofsky 60-100%
- At least 12 weeks
- See Disease Characteristics
- Bilirubin < 2.0 times upper limit of normal (ULN)*
- SGOT < 2.5 times ULN*
- Creatinine < 1.5 times ULN
- No history of cardiac arrhythmia
- No myocardial infarction within the past 6 months
- No other malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix
- No active serious infection uncontrolled by antibiotics
- No pre-existing neurotoxicity grade 3 or greater
- No other medical condition that would preclude study participation
- Not pregnant or nursing
- Negative pregnancy test
- Female patients must use 2 effective methods (at least 1 highly active method) of contraception 4 weeks before, during, and for 4 weeks after study participation and male patients must use effective barrier contraception during and for 4 weeks after study participation
- At least 4 weeks since prior biologic therapy and recovered
- No concurrent growth factors (epoetin alfa, filgrastim [G-CSF], or sargramostim [GM-CSF])
- See Disease Characteristics
- No more than 3 prior chemotherapy regimens
- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered
- No other concurrent chemotherapy
- At least 4 weeks since prior radiotherapy and recovered
- No concurrent radiotherapy
- Recovered from any prior investigational agents
- No other concurrent investigational agents
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Arm I (thalidomide)
Patients receive oral thalidomide once daily in the absence of disease progression or unacceptable toxicity.
|
Ges oralt
Andra namn:
|
|
Experimentell: Arm II (thalidomide, fludarabine phosphate)
Patients receive thalidomide as in arm I and fludarabine IV over 30 minutes on days 1-5.
Treatment with fludarabine repeats every 28 days for 6 courses.
Once fludarabine is completed, patients continue to receive thalidomide alone as in arm I.
|
Givet IV
Andra namn:
Ges oralt
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Toxicities graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0
Tidsram: Up to 5 years
|
Up to 5 years
|
|
Incidence of complete and partial remission
Tidsram: Up to 5 years
|
Up to 5 years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Richard Furman, Montefiore Medical Center
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Immunsystemets sjukdomar
- Neoplasmer efter histologisk typ
- Neoplasmer
- Lymfoproliferativa störningar
- Lymfatiska sjukdomar
- Immunproliferativa störningar
- Leukemi, B-cell
- Leukemi
- Leukemi, lymfocytisk, kronisk, B-cell
- Leukemi, lymfoid
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antimetaboliter, antineoplastiska
- Antimetaboliter
- Antineoplastiska medel
- Immunsuppressiva medel
- Immunologiska faktorer
- Angiogeneshämmare
- Angiogenesmodulerande medel
- Tillväxtämnen
- Tillväxthämmare
- Antibakteriella medel
- Leprostatiska medel
- Talidomid
- Fludarabin
- Fludarabinfosfat
Andra studie-ID-nummer
- NCI-2012-02393
- N01CM62204 (U.S.S. NIH-anslag/kontrakt)
- NYWCCC-MTS-00-0535ME
- CDR0000068429
- NCI-639
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .